With a 4-0 vote, the FTC has approved final consent orders remedying the anticompetitive effects of Valeant Pharmaceuticals’ proposed acquisitions of Sanofi and Johnson & Johnson’s dermatalogy businesses. For the Sanofi deal, Valeant has sold to Mylan Pharmaceuticals the manufacturing and marketing rights to products treating acne and actinic keratosis. For the Johnson & Johnson deal, Valeant has sold to Spear Pharmaceuticals the rights to an anti-wrinkle pharmaceutical product.
The orders settle charges of Section 7 Clayton Act and Section 5 FTC Act violations.
Source: FTC Press Release
Related content: Consumer Protection Economics at the FTC
Featured News
FTC and State Attorneys General Sue John Deere Over Repair Restrictions in Antitrust Case
Jan 15, 2025 by
CPI
Enbridge Wins Legal Battle Against Ducere’s Antitrust Allegations
Jan 15, 2025 by
CPI
GOP Pushes for Antitrust Authority Consolidation Under DOJ in New Legislation
Jan 15, 2025 by
CPI
Canadian Government Approves Bunge-Viterra Merger with Conditions
Jan 15, 2025 by
CPI
SEC Sues Elon Musk Over Delayed Disclosure of Twitter Stock Ownership
Jan 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – CRESSE Insights
Dec 19, 2024 by
CPI
Effective Interoperability in Mobile Ecosystems: EU Competition Law Versus Regulation
Dec 19, 2024 by
Giuseppe Colangelo
The Use of Empirical Evidence in Antitrust: Trends, Challenges, and a Path Forward
Dec 19, 2024 by
Eliana Garces
Some Empirical Evidence on the Role of Presumptions and Evidentiary Standards on Antitrust (Under)Enforcement: Is the EC’s New Communication on Art.102 in the Right Direction?
Dec 19, 2024 by
Yannis Katsoulacos
The EC’s Draft Guidelines on the Application of Article 102 TFEU: An Economic Perspective
Dec 19, 2024 by
Benoit Durand